Meta AnalysisID 6661
口服中成药治疗肝郁脾虚型抑郁症的疗效与安全性：网状Meta分析
CRD42019115695
The subjects of the study were patients with depression of liver stagnation and spleen deficiency type, whose age, gender and race of are unlimited. The intervention measures were three kinds of Chinese patent medicine w
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6661
- Evidence Id
- 15219
- Core Evidence Id
- 15219
- Source Meta Analysis Id
- 6644
- Herb2 Meta Analysis Id
- HBMA006644
- Crd Id
- CRD42019115695
- Title
- Efficacy and safety of oral traditional Chinese patent medicine in treatment of liver stagnation and spleen deficiency of depression: a network meta-analysis
- Review Question
- The subjects of the study were patients with depression of liver stagnation and spleen deficiency type, whose age, gender and race of are unlimited. The intervention measures were three kinds of Chinese patent medicine which were the most targeted, representative, highest ranked and most commonly used in the clinical treatment of depression of liver depression and spleen deficiency, respectively, Shugan Jieyu capsule, Jieyu pill and Xiaoyao Pill were combined with fluoxetine respectively, while the control group was treated with fluoxetine. The outcome indicators were clinical efficiency, HAMD and TESS. All the three kinds of Chinese patent medicine adjuvant therapy have clinical comparability, but their actual efficacy and safety are lack of evidence. Therefore, we use the Network Meta-analysis method to obtain the clinical efficiency, HAMD and TESS score of these three kinds of Chinese patent medicine adjuvant therapy, and then according to the advantages and disadvantages of the index efficacy, we rank the probability, and then select the best clinical treatment measures, in order to be temporary, BED provides the best choice of drugs and reliable evidence-based medicine.
- Study Type Included
- Included in the randomized controlled trial, no restrictions on literacy and blindness. At the same time, the patients included in the depression of liver depression and spleen deficiency type should conform to the third edition of Chinese standard for classification and diagnosis of mental disorders (CCMD-3), the international standard for classification of diseases (ICD-10), the American manual for diagnosis and statistics of mental disorders (DSM-V), the diagnostic standard of syndrome type of traditional Chinese medicine (TCM) and other diagnostic standards, such as the diagnostic efficacy standard of syndrome type of traditional Chinese medicine (TCM) or the syndrome differentiation standard of TCM. The exclusion criteria include non-randomized controlled trials, case reports, experience summaries, self-control and review literature, animal experimental studies, simple descriptive literature, repeatedly published literature, literature with unclear diagnosis of depression or other diseases, literature with unclear research results, incomplete data or no connection with the full text author were excluded.
- Condition Being Studied
- Depression is a mental and psychological disorder that has long plagued human health. It is characterized by high incidence, recurrence and disability rate, and has the highest incidence among all kinds of mental diseases. It is one of the common diseases that seriously threaten human health. Depression seriously disturbs people's normal work, study and life, and its high suicide rate has a direct impact on social stability, increasing the global burden of disease and disability. Therefore, the research on the prevention and treatment of depression has become one of the focus areas of all mankind.
- Participant
- Randomized controlled trial (RCT), patients with single liver depression and spleen deficiency type of depression, age, gender, race. The diagnostic criteria of depression should meet the third edition of Chinese classification and diagnostic criteria of mental disorders (ccmd-3), the international standard of disease classification (icd-10) or the standard of American diagnostic and statistical manual of mental disorders (dsm-v), and the diagnostic criteria of TCM syndromes should meet the standard of diagnosis and efficacy of TCM diseases and syndromes or the standard of TCM syndrome differentiation.
- Animal
- Human Disease Modelled
- Intervention
- With clear diagnostic criteria and efficacy criteria and consistent basic treatment, the experimental group was treated with proprietary Chinese medicine (shugan jieyu capsule or jieyu pill or xiaoyao pill) or (shugan jieyu capsule or jieyu pill or xiaoyao pill) combined with fluoxetine, while the control group was treated with fluoxetine
- Comparator Control
- While the control group was treated with fluoxetine
- Main Outcome
- 1. clinical efficiency; 2. HAMD score (Hamilton depression scale); 3. TESS (adverse reaction symptom scale). Measures of effect The treatment period is four to eight weeks
- Outcome Measure
- Additional Outcome
- None Measures of effect Not applicable.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Depression; Humans; Liver; Medicine, Chinese Traditional; Mind-Body Therapies; Network Meta-Analysis; Spleen
- Contact
- Ying Yu [email protected]
- Organisational Affiliation
- Medical College http://www.sdutcm.edu.cn/
- Funding Source
- Mechanism and efficacy evaluation of the first group of excellent scientific research and innovation teams of shandong university of traditional Chinese medicine（220316）
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2019-07-20
- Registration Date
- 2019-11-11
- Anticipated Start Date
- 2019-07-20
- Anticipated Completion Date
- 2019-11-01
- Title Cn
- 口服中成药治疗肝郁脾虚型抑郁症的疗效与安全性：网状Meta分析
- Title En
- Efficacy and safety of oral traditional Chinese patent medicine in treatment of liver stagnation and spleen deficiency of depression: a network meta-analysis
- Bilingual Status
- complete